Next Article in Journal
A Tale of Two Cities”: Anticoagulation Management in Patients with Atrial Fibrillation and Prosthetic Valves in the Era of Direct Oral Anticoagulants
Previous Article in Journal
Association of SOD2 (rs4880) and GPX1 (rs1050450) Gene Polymorphisms with Risk of Balkan Endemic Nephropathy and its Related Tumors
Article Menu

Export Article

Open AccessArticle

Polypharmacy in Type 2 Diabetes Mellitus: Insights from an Internal Medicine Department

1
“Carol Davila” University of Medicine and Pharmacy, 8 Eroii Sanitari Boulevard, Bucharest 050474, Romania
2
Emergency University Central Military Hospital, 88 Mircea Vulcanescu Street, Bucharest 010825, Romania
3
Academy of Romanian Scientists, 54 Splaiul Independentei Street, Bucharest 030167, Romania
4
Internal Medicine Clinic, Clinical Emergency Hospital of Bucharest, 8 Calea Floreasca Street, Bucharest 014461, Romania
*
Author to whom correspondence should be addressed.
Medicina 2019, 55(8), 436; https://doi.org/10.3390/medicina55080436
Received: 18 May 2019 / Revised: 20 July 2019 / Accepted: 31 July 2019 / Published: 3 August 2019
  |  
PDF [504 KB, uploaded 6 August 2019]
  |  

Abstract

Background and Objectives: Polypharmacy heavily impacts the quality of life of patients worldwide. It is a necessary evil in many disorders, and especially in type 2 diabetes mellitus, as patients require treatment both for this condition and its related or unrelated comorbidities. Thus, we aimed to evaluate the use of polypharmacy in type 2 diabetes mellitus vs. non-diabetes patients. Materials and Methods: A cross-sectional retrospective observational study was conducted. We collected the medical records of patients hospitalized in the Internal Medicine Clinic of the Clinical Emergency Hospital of Bucharest, Romania, for a period of two months (01/01/2018–28/02/2018). Patients diagnosed with type 2 diabetes mellitus were included in the study group, whereas patients who were not diabetic were used as controls. Results: The study group consisted of 63 patients with type 2 diabetes mellitus (mean age 69.19 ± 9.67 years, range 46–89 years; 52.38% males). The control group included 63 non-diabetes patients (mean age 67.05 ± 14.40 years, range 42–93 years, 39.68% males). Diabetic patients had more comorbidities (10.35 ± 3.09 vs. 7.48 ± 3.59, p = 0.0001) and received more drugs (7.81 ± 2.23 vs. 5.33 ± 2.63, p = 0.0001) vs. non-diabetic counterparts. The mean number of drug-drug and food-drug interactions was higher in type 2 diabetes mellitus patients vs. controls: 8.86 ± 5.76 vs. 4.98 ± 5.04, p = 0.0003 (minor: 1.22 ± 1.42 vs. 1.27 ± 1.89; moderate: 7.08 ± 4.08 vs. 3.54 ± 3.77; major: 0.56 ± 0.74 vs. 0.37 ± 0.77) and 2.63 ± 1.08 vs. 2.19 ± 1.42 (p = 0.0457), respectively. Conclusions: Polypharmacy should be an area of serious concern also in type 2 diabetes mellitus, especially in the elderly. In our study, type 2 diabetes mellitus patients received more drugs than their non-diabetes counterparts and were exposed to more drug-drug and food-drug interactions. View Full-Text
Keywords: diabetes mellitus; polypharmacy; drug-drug interactions; food-drug interactions; comorbidities; multimorbidity; elderly diabetes mellitus; polypharmacy; drug-drug interactions; food-drug interactions; comorbidities; multimorbidity; elderly
Figures

Figure 1

This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited (CC BY 4.0).
SciFeed

Share & Cite This Article

MDPI and ACS Style

Dobrică, E.-C.; Găman, M.-A.; Cozma, M.-A.; Bratu, O.G.; Pantea Stoian, A.; Diaconu, C.C. Polypharmacy in Type 2 Diabetes Mellitus: Insights from an Internal Medicine Department. Medicina 2019, 55, 436.

Show more citation formats Show less citations formats

Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Metrics

Article Access Statistics

1

Comments

[Return to top]
Medicina EISSN 1010-660X Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top